Chad R. Ritch, MD, MBA, FACS, discusses how PSMA-PET informs staging, treatment planning, recurrence workup, and the interpretation of equivocal findings.
PSMA-PET in Prostate Cancer: Evidence and Practice
Advertisement
Advertisement
Trending on Urology Times
1
Michael Cookson, MD, reacts to Anktiva’s expanded approval in NMIBC
2
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
ESMO 2026: Key presentations across genitourinary oncology
5